OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TRAW
Traws Pharma, Inc.
There isn't enough reported data to score TRAW yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TRAW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRAW's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TRAW PE Valuation
TRAW has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TRAW Forward outlook
There aren't enough analyst estimates for TRAW to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TRAW on earnings quality, reporting a profit while its opponent remains loss making.
TRAW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.85 | +$26.27 |
| Q1 2026 | -$1.80 | +$147.96 |
| Q4 2025 | $0.82 | +$158.67 |
| Q3 2025 | -$19.65 | +$121.66 |
| Q2 2025 | -$28.12 | +$110.13 |
| Q1 2025 | -$149.76 | -$128.26 |
| Q4 2024 | -$157.85 | -$135.35 |
| Q3 2024 | -$141.31 | -$117.06 |
TRAW lost $1.85 per share over the past year, a smaller loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 100% for TRAW.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TRAW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.7M | +4695% |
| Q1 2025 | $57K | +1.8% |
| Q4 2024 | $56K | 0% |
| Q3 2024 | $57K | 0% |
| Q2 2024 | $57K | 0% |
| Q1 2024 | $56K | 0% |
| Q4 2023 | $56K | 0% |
| Q3 2023 | $57K | 0% |
TRAW's revenue has picked up after four years of holding roughly level: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -46% | +216354 points |
| Q1 2025 | -9128% | +179 points |
| Q4 2024 | -9425% | -1457 points |
| Q3 2024 | -14975% | -6047 points |
| Q2 2024 | -216400% | -208312 points |
| Q1 2024 | -9307% | +1652 points |
| Q4 2023 | -7968% | +2271 points |
| Q3 2023 | -8928% | +968 points |
TRAW's operating margin was −46% last quarter, up 216354 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
TRAW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.6M | +$2.9M |
| Q4 2025 | -$2.8M | +$1.3M |
| Q1 2025 | -$5.4M | -$1M |
| Q4 2024 | -$4M | +$390K |
| Q1 2024 | -$4.4M | +$119K |
| Q4 2023 | -$4.4M | -$546K |
| Q2 2023 | -$4.5M | -$276K |
| Q1 2023 | -$4.5M | -$247K |
TRAW has burned cash in almost every quarter: −$18M over the past year, against −$24M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over TRAW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TRAW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +49% | +5.2M shares |
| 1 year | +120% | +8.6M shares |
| 3 years | +1797% | +15M shares |
| 5 years | +3318% | +15.4M shares |
| Available history | +96762% | +15.8M shares |
TRAW has 16M diluted shares, up 120% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TRAW Net Leverage
TRAW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TRAW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 5.5 | Oversold |
TRAW's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRAW PE vs Healthcare Sector
TRAW has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TRAW on trend strength, trading above more of its moving averages.
TRAW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.39 | 28% below |
| 20 week MA | $0.50 | 44% below |
| 50 week MA | $1.19 | 76% below |
| 100 week MA | $2.12 | 87% below |
| 200 week MA | $9.74 | 97% below |
TRAW is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TRAW on returns for 2026, with the stronger performance.
TRAW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.8 | $176.3 | +15% |
| 2021 | $176.3 | $71.3 | -60% |
| 2022 | $71.3 | $16.5 | -77% |
| 2023 | $16.5 | $18.8 | +14% |
| 2024 | $18.8 | $13.4 | -28% |
| 2025 | $13.4 | $1.17 | -91% |
| 2026 YTD | $1.17 | $0.28 | -76% |
TRAW has finished lower in four of the last six years. It's down 76% so far in 2026.